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Background
Studying phenotypic and genetic characteristics of age at onset
(AAO) and polarity at onset (PAO) in bipolar disorder can provide
new insights into disease pathology and facilitate the develop-
ment of screening tools.
Aims
To examine the genetic architecture of AAO and PAO and their
association with bipolar disorder disease characteristics.
Method
Genome-wide association studies (GWASs) and polygenic score
(PGS) analyses of AAO (n = 12 977) and PAO (n = 6773) were
conducted in patients with bipolar disorder from 34 cohorts and
a replication sample (n = 2237). The association of onset with
disease characteristics was investigated in two of these cohorts.
Results
Earlier AAO was associated with a higher probability of psychotic
symptoms, suicidality, lower educational attainment, not living
together and fewer episodes. Depressive onset correlated with
suicidality and manic onset correlated with delusions and manic
episodes. Systematic differences in AAO between cohorts and
continents of origin were observed. This was also reflected in
single-nucleotide variant-based heritability estimates, with higher
heritabilities for stricter onset definitions. Increased PGS for autism
spectrum disorder (β =−0.34 years, s.e. = 0.08), major depression
(β =−0.34 years, s.e. = 0.08), schizophrenia (β =−0.39 years, s.e. =
0.08), and educational attainment (β =−0.31 years, s.e. = 0.08)
were associated with an earlier AAO. The AAO GWAS identified
one significant locus, but this finding did not replicate. Neither
GWAS nor PGS analyses yielded significant associations with PAO.
Conclusions
AAO and PAO are associated with indicators of bipolar disorder
severity. Individuals with an earlier onset show an increased
polygenic liability for a broad spectrum of psychiatric traits.
Systematic differences in AAO across cohorts, continents and
phenotype definitions introduce significant heterogeneity,
affecting analyses.
Keywords
Bipolar disorder; age at onset; polarity at onset; GWAS; polygenic
score.
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Background
Bipolar disorder is highly heritable and affects approximately 1% of
the population. It has a recurrent or chronic course and is associated
with psychosocial impairment and reduced functioning, and it is a
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leading cause of global disease burden.1 Individuals usually experi-
ence their first (hypo)manic or depressive episode of bipolar dis-
order in adolescence or early adulthood, but often they are not
diagnosed until 5 to 10 years later,2 especially in individuals with
an earlier age at onset (AAO) or a depressive index episode.3
Early illness onset is associated with a more severe disease course
and greater impairment across a wide range of mental and physical
disorders and is a useful prognostic marker.4–7 However, patho-
physiological processes leading to a disorder are thought to begin
long before the first symptoms appear.8,9 Investigating the factors
contributing to age and polarity (i.e. either a (hypo)manic or depres-
sive episode) at onset could thus improve our understanding of
disease pathophysiology and facilitate development of personalised
screening and preventive measures. Accordingly, AAO and polarity
at onset (PAO) of bipolar disorder are considered as suitable pheno-
types for genetic analyses.
Genome-wide association studies (GWASs) have improved our
understanding of the genetic architecture of susceptibility to bipolar
disorder; however, the genetic determinants of AAO and PAO
remain largely unknown. Evidence suggests that patients with an
early AAO carry a stronger genetic loading for bipolar disorder
risk.10 For example, an earlier parental AAO increases familial
risk for bipolar disorder and is one of the strongest predictors of
5-year illness onset in affected offspring.10–12 Previous research
has described that a higher genetic risk burden for schizophrenia
may be associated with earlier AAO of bipolar disorder,13 but this
finding did not replicate.14–16 Moreover, a recent study did not
find an association of bipolar disorder polygenic score (PGS) with
AAO.17 Thus far, GWASs for age at bipolar disorder onset have
been underpowered,18,19 and a study of 8610 patients found no sig-
nificant evidence for a heritable component contributing to onset
age.13 The PAO was shown to cluster in families,20 but the genetic
architecture of PAO has not yet been investigated.
Aims
To fill these knowledge gaps, we performed comprehensive analyses
of AAO and PAO of bipolar disorder in the largest sample studied
to date by (a) examining phenotype definitions and associations,
(b) investigating whether the genetic load for neuropsychiatric dis-
orders and traits contributes to AAO and PAO of bipolar disorder,
and (c) conducting systematic GWASs.
Method
References to publishedmethods are listed in Supplementary Note 1
available at https://doi.org/10.1192/bjp.2021.102.
Study samples
Participants with a bipolar disorder diagnosis, available genetic data
and AAO information were selected from independent data-sets,
including those previously submitted to the Psychiatric Genomics
Consortium (PGC) Bipolar Disorder Working Group13 and the
International Consortium on Lithium Genetics (ConLiGen).21
These consortia aggregate genetic data from many cohorts world-
wide. Our analyses comprised 34 cohorts with 12 977 patients
with bipolar disorder who have European ancestry from Europe,
North America and Australia. For a description of sample ascertain-
ment, see the Supplementary Material.
The authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national and insti-
tutional committees on human experimentation and with the
Helsinki Declaration of 1975, as revised in 2008. All procedures
involving human patients were approved by the local ethics
committees, and written informed consent was obtained from all
patients. For details on the data-sets, including phenotype definitions
and distributions, see Table 1, Fig. 1, and Supplementary Table S1.
Definition of AAO
The definition of age at bipolar disorder onset differed by cohort. To
enhance cross-cohort comparability, we grouped the definitions
into four broad categories as follows (Supplementary Table S1).
(a) Diagnostic interview: age at which the patient first experienced
a (hypo)manic, mixed or major depressive episode according to
a standardised diagnostic interview.
(b) Impairment/help-seeking: age at which symptoms began to
cause subjective distress or impaired functioning or at which
the patient first sought psychiatric treatment.
(c) Pharmacotherapy: age at first administration of medication.
(d) Mixed: a combination of the above-mentioned definitions.
Across definitions, participants younger than 8 years at onset were
excluded (n = 279) because of the uncertainty about the reliability of
retrospective recall of early childhood onset. The distribution of
AAO was highly skewed and differed considerably between the
cohorts (Table 1 and Fig. 1). Therefore, we transformed AAO in
each cohort by rank-based inverse-normal transformation and
used this normalised variable as the primary dependent variable
in all genetic analyses. To facilitate interpretability of effect sizes,
we also report results of the corresponding untransformed AAO.
Definition of PAO
For each cohort, PAO was defined by comparing the age at the first
(hypo)manic and first depressive episode or using the polarity vari-
able provided by the cohort. Specifically, patients were divided into
three subgroups:
(a) (hypo)mania before depression (PAO-M);
(b) depression before (hypo)mania (PAO-D); and
(c) mixed (PAO-X).
The third category included patients with mixed episodes and those
with a first (hypo)manic and depressive episode within the same
year (Table 1). In the primary analysis, we combined patients
with (hypo)mania and mixed onset and assigned this as the refer-
ence category. In secondary analyses, we excluded the patients in
the mixed group.
Phenotypic disease characteristics
We performed phenotypic analyses of disease onset in patients with
bipolar disorder type I from three cohorts: the Dutch Bipolar cohort
(n = 1313)22 and the German PsyCourse23 and FOR210724 cohorts,
which were analysed jointly (n = 346). We analysed the following
disease characteristics, which were previously reported as being
associated with disease onset and were assessed in a similar way
across cohorts: lifetime delusions, lifetime hallucinations, history
of suicide attempt, suicidal ideation, current smoking, educational
attainment, living together with a partner, and frequency of manic
and depressive episodes per year. For more detailed information,
see the Supplementary Note 2 and Supplementary Table S9.
Quality control and imputation of genotype data
The cohorts were genotyped according to local protocols. Individual
genotype data of all discovery-stage cohorts were processed with the
PGC Rapid Imputation and Computational Pipeline for GWAS
(RICOPILI) with the default parameters for standardised quality
control, imputation and analysis. Before imputation, filters for the
removal of variants included non-autosomal chromosomes, missing-
ness ≥0.02, and a Hardy–Weinberg equilibrium test P < 1 × 10−10.
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Table 1 Sample characteristics of data-sets used in genetic analyses
GWAS stage, dataset n Continent Diagnosis, % bipolar disorder type I Gender, % male AAO, median (MAD,a range) Definition of AAO PAO,b n (%)
Discovery
wtccc 1452 Europe 89.53 36.85 24 (8.9, 9–63) Impairment/help-seeking
tgco2 865 North America 100 33.64 17 (5.93, 8–46) Diagnostic interview PAO-M: 316 (38.92); PAO-D: 496 (61.08)
gain 797 North America 100 48.06 18 (5.93, 8–45) Diagnostic interview PAO-M: 135 (18.57); PAO-D: 440 (60.52)
stp1 718 North America 100 44.01 16 (5.93, 8–41) Diagnostic interview PAO-M: 137 (19.08); PAO-D: 420 (58.5)
gsk1 715 North America 89.51 36.36 19 (7.51, 8–52) Diagnostic interview PAO-M: 102 (14.61); PAO-D: 395 (56.59)
usc2 681 North America 96.18 47.58 18 (7.41, 8–48) Impairment/help-seeking
bonn 638 Europe 99.84 47.34 25 (8.9, 9–64) Impairment/help-seeking
ucl2 604 Europe 100 44.37 30 (11.86, 9–60) Pharmacotherapy PAO-M: 47 (9.96); PAO-D: 209 (44.28)
bmg3 455 Europe 57.14 40.66 24 (10.38, 10–62) Impairment/help-seeking PAO-M: 43 (16.35); PAO-D: 159 (60.46)
m&m’s 449 Europe 74.83 52.12 23 (10.38, 8–65) Mixed PAO-M: 73 (17.14); PAO-D: 238 (55.87)
uclo 439 Europe 100 39.86 22 (7.41, 8–51) Impairment/help-seeking PAO-M: 54 (14.25); PAO-D: 197 (51.98)
fran 411 Europe 77.62 41.36 22 (7.41, 10–58) Diagnostic interview
euoR 410 Europe 75.85 44.15 22 (9.64, 11–59) Mixed
hal2 355 North America 71.55 42.54 23 (8.9, 8–56) Diagnostic interview PAO-M: 102 (29.65); PAO-D: 213 (61.92)
ume4 354 Europe 69.21 37.85 20 (8.9, 8–63) Diagnostic interview PAO-M: 54 (14.25); PAO-D: 197 (51.98)
swa2 344 Europe 81.10 41.86 23 (10.38, 10–70) Impairment/help-seeking
bmpo 319 Europe 78.06 39.18 28 (11.86, 10–63) Impairment/help-seeking PAO-M: 41 (16.33); PAO-D: 150 (59.76)
top7 301 Europe 62.79 41.53 19 (7.41, 8–49) Diagnostic interview
may1 257 North America 100 45.14 20 (8.9, 8–62) Diagnostic interview PAO-M: 34 (13.23); PAO-D: 142 (55.25)
bmsp 248 Europe 94.76 45.56 22 (7.41, 9–57) Impairment/help-seeking PAO-M: 24 (10.04); PAO-D: 93 (38.91)
bmau 245 Australia 79.18 40.82 19 (7.41, 8–55) Diagnostic interview PAO-M: 46 (20.18); PAO-D: 125 (54.82)
edi1 244 Europe 99.18 42.62 20 (5.93, 13–50) Diagnostic interview
rom3 226 Europe 100 41.15 25 (10.38, 12–59) Diagnostic interview PAO-M: 91 (40.27); PAO-D: 134 (59.29)
butr 204 Europe 100 40.2 22 (5.19, 13–44) Impairment/help-seeking
euoI 191 Europe 74.87 31.41 24 (8.9, 13–67) Diagnostic interview PAO-M: 48 (27.43); PAO-D: 98 (56)
ageu 178 Europe 90.45 39.33 21 (7.41, 8–51) Impairment/help-seeking
mich 169 North America 100 31.36 18 (5.93, 8–45) Diagnostic interview PAO-M: 42 (24.85); PAO-D: 84 (49.7)
naom 159 North America 84.91 44.65 18 (7.41, 8–66) Mixed PAO-M: 30 (28.85); PAO-D: 51 (49.04)
bmg2 152 Europe 59.87 35.53 27 (10.38, 13–63) Impairment/help-seeking
top8 111 Europe 55.86 37.84 18 (7.41, 8–49) Diagnostic interview
h66x 92 Europe 82.61 36.96 30 (10.38, 9–55) Mixed
auom 85 Australia 88.24 45.88 25 (10.38, 8–64) Diagnostic interview
euo2 58 Europe 65.52 56.9 26 (8.9, 18–57) Diagnostic interview
dub1 51 Europe 100 54.9 21 (5.93, 12–45) Diagnostic interview
Summary 12 977 88.27 41.57 21 (8.9, 8–70) PAO–M: 1435 (21.19); PAO-D: 3885 (57.36)
Replication
ukwa1 1156 Europe 75.17 38.15 23 (8.9, 8–74) Impairment/help-seeking
dutch 468 Europe 100 42.31 28 (10.38, 11–63) Pharmacotherapy
jst5 186 North America 100 53.23 16 (7.41, 8–51) Unknown
colo 176 South America 90.34 31.82 20 (11.86, 8–52) Diagnostic interview
bmrom 126 Europe 100 42.86 24 (8.9, 12–56) Diagnostic criteria
bdtrs 125 Europe 64 45.6 28 (13.34, 8–65) Impairment/help-seeking
Summary 2237 84.40 40.46 24 (10.38, 8–74)
All data 15 214 86.26 41.41 22 (8.9, 8–74)
GWAS, genome-wide association study; AAO, age at onset; MAD, median absolute deviation, PAO, polarity at onset; PAO-M, mania/hypomania before depression; PAO-D, depression before mania/hypomania.
a. We calculated the median absolute deviation using 1.4826 as constant.
b. We defined three categories of polarity at onset: PAO-M,mania/hypomania before depression; PAO-D, depression beforemania/hypomania; and PAO-X, mixed. PAOwas not available for all patients. The table presents the PAO-M and PAO-D subgroups and their percentage
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Individuals were removed if they showed a genotyping rate ≤0.98,
absolute deviation in autosomal heterozygosity of Fhet≥0.2, or a devi-
ation >4 s.d.s from the mean in any of the first eight ancestry compo-
nents within each cohort. From genetic duplicates and relatives (pi-
hat >0.2) across all samples, only the individual with more complete
phenotypic information on AAO and PAO, gender and diagnosis
was retained. Imputation was performed by IMPUTE2 with the
Haplotype Reference Consortium reference panel.
PGS
We calculated PGS based on prior GWAS of attention-deficit hyper-
activity disorder (ADHD), autism spectrum disorder (ASD), bipolar
disorder, educational attainment (measured as ‘years in education’),
major depression (MD), and schizophrenia (see Supplementary
Table S3, which includes references). PGS weights were estimated
with PRS-CS(see Supplement), with six scores per GWAS (with φ
= 1 × 10−1, 1 × 10−2, 1 × 10−3, 1 × 10−4, 1 × 10−5, and 1 × 10−6).
We tested the associations of the PGS with the AAO and PAO by
linear and logistic regressions, respectively. Gender, bipolar disorder
subtype and the first eight ancestry components were included as
covariates. The significance threshold was Bonferroni-corrected
for 96 tests (α = 0.05/(6 φ thresholds × 8 traits × 2 phenotypes) =
5.2 × 10−4).
GWASs
We performed a discovery GWAS on the 34 cohorts (n = 12 977)
and replication analyses in six additional cohorts with n = 2237
patients with bipolar disorder. As a first step, we conducted individ-
ual GWAS for each cohort with 40 or more patients using the
RICOPILI workflow, using the same covariates as in the PGS ana-
lyses. Sample sizes are provided in Supplementary Tables S2 and
S7. The resulting GWAS did not show an inflation of test statistics
for any of the cohorts, indicating limited population stratification
(Supplementary Table S2). Next, we performed a fixed-effects
meta-analysis using METAL, combining the cohort-specific
GWASs. For the meta-analysis summary statistics, we applied the
following variant-level post-quality control parameters: imputation
INFO score≥0.9, minor allele frequency (MAF) ≥0.05, and suc-
cessfully imputed/genotyped in more than half of the cohorts.
The primary analyses were AAO (normalised, analysed by
linear regression) and PAO (analysed by logistic regression).
Secondary analyses included GWASs stratified by AAO definition
and continent of origin.
We estimated the power to replicate our initial genome-wide
significant finding from the discovery GWAS based on the regres-
sion coefficients using the pwr package in R. Assuming the same
effect size and MAF (beta 0.075, allele frequency 0.32) and a stan-
dardised phenotype, we had 76% power to detect the effect in our
sample size of 2237 at an alpha level of 0.1. For comparison, we
had 57% power to detect the effect in our discovery sample, using
the more stringent genome-wide significance cut-off.
Heritability analyses
Next, we assessed the overall variance in AAO and PAO explained
by genotyped variants (so-called single-nucleotide variant (SNV)-
based heritability, h2SNV). For the only individual cohort with more
than 1000 samples, we estimated h2SNV with GCTA GREML. In









































































































































Fig. 1 Differences between phenotype definitions and continents across the 34 data-sets used for discovery-stage genetic analyses.
(a) The various data-sets used four different definitions for age at onset: diagnostic interview, impairment/help-seeking, pharmacotherapy and mixed. (b) The untransformed age at
onset differed significantly between cohorts, depending on the phenotype definition used and the continent of origin.
Au, Australia; Diagnostic, diagnostic interview; D, diagnostic interview; I, impairment/help-seeking; M, mixed; P, pharmacotherapy. n.s., not significant; P > 0.05; *** P < 0.001.
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the mean of 1000 × resampling of 95% of the sample. To estimate
the overall heritability of the meta-analysis summary statistics we
estimated h2SNV by linkage disequilibrium score regression, for
each GWAS with sample size >3000. The 95% CIs were constrained
to a minimum of 0 and a maximum of 1.
Results
Heterogeneity of AAO and PAO across cohorts
Among the four definitions of AAO across the 34 cohorts, impair-
ment/help-seeking was the most common in Europe and diagnostic
interview the most common in North America (Table 1, Fig. 1).
Across all cohorts, the median AAO was 21 years (range of
medians: 16–30 years; Fig. 1). However, substantial differences in
the AAO were observed between subgroups: first, the median
untransformed AAO was lower in bipolar disorder type I than
in type II (type I, 21 years; type II, 22 years; Kruskal-Wallis test
P = 1.8 × 10−4; Supplementary Table S6).
Second, the AAO was lower when determined by diagnostic
interview compared with other phenotype definitions (diagnostic
interview, 19 years; impairment/help-seeking, 23 years; pharmaco-
therapy, 30 years; mixed, 22 years; P = 2.96 × 10−191). Third, the
age was lower in North America compared with Europe (Europe,
24 years; North America, 18 years; and Australia, 19.5 years; P =
2.0 × 10−263). These differences across continents remained signifi-
cant when including onset definitions and bipolar disorder subtype
in a multivariable regression model, indicating that they are likely
partially independent from the assessment strategy (Supplementary
Table S6).
The majority of patients reported a depression-first PAO.
Patients with depression-first were less frequent in the impair-
ment/help-seeking than in the diagnostic interview category (55%
and 60%, respectively; P = 4.5 × 10−4, Supplementary Fig. S1), but
their proportions were similar between Europe and North
America (57% and 59%, respectively; P = 0.17 test of proportion).
Analyses of disease characteristics
In a meta-analysis of the Dutch and German samples, earlier AAO
was significantly associated with a higher probability of lifetime
delusions, hallucinations, suicide attempts, suicidal ideation, lower
educational attainment and not living together (Table 2,
Supplementary Tables S4 and S5). A later AAO was positively sig-
nificantly correlated with a higher number of manic and depressive
episodes per year (see Tables 3, and the Supplementary Note 2).
Moreover, a (hypo)manic onset was significantly associated with a
greater likelihood of delusions and more manic episodes per year,
whereas a depressive onset was associated with a higher probability
of suicidal ideation and lifetime suicide attempts.
Associations of PGSs with AAO and PAO
Next, we conducted analyses to evaluate whether the genetic liability
for five psychiatric disorders and educational attainment were asso-
ciated with the age at disease onset (Fig. 2(a) and (b) and
Supplementary Table S8). After correcting for 96 tests, higher
PGSs for ASD (β =−0.34 years per 1 s.d. increase in PGS, s.e. =
0.08, P = 9.85 × 10−6), major depression (β =−0.34, s.e. = 0.08, P =
1.40 × 10−6), schizophrenia (β =−0.39, s.e. = 0.08, P = 2.91 × 10−6)
and educational attainment (β =−0.31, s.e. = 0.08, P = 5.58 × 10−5)
were significantly associated with an earlier age at bipolar disorder
onset. This was not the case for ADHD or bipolar disorder PGS. No
PGS was significantly associated with PAO (Supplementary Fig. S4,
Supplementary Table S8).
GWASs
Next, we attempted to identify individual genetic loci associated with
the AAO or PAO. In our discovery GWAS using 34 cohorts, one
locus was significantly associated with AAO (rs1610275 on chromo-
some 16; minor allele G frequency = 0.319, β = 0.075 (s.e. = 0.014),
P = 3.39 × 10−8, Fig. 2(c), Supplementary Table S7, Supplementary
Fig. S2). This SNV mapped to an intron of the brain-expressed
gene FTO (alpha-ketoglutarate dependent dioxygenase, Fig. 2(d)).
Table 2 The association of age and polarity at onset with disease characteristics in two European bipolar disorder cohorts
Disease characteristic
AAO PAO
n Odds ratio 95% CI Unadjusted P Adjusted Pa n Odds ratio 95% CI Unadjusted P Adjusted P
Delusions 1612 0.71 0.64–0.79 1.61 × 10−9 1.45 × 10−8* 1298 0.62 0.49–0.79 1.04 × 10−4 6.24 × 10−4*
Hallucinations 1594 0.83 0.74–0.92 3.5 × 10−4 1.40 × 10−3* 1290 0.93 0.74–1.17 5.22 × 10−1 1.00 × 100
Current smoking 1594 0.98 0.89–1.09 7.50 × 10−1 7.50 × 10−1 1282 1.12 0.89–1.41 3.39 × 10−1 1.00 × 100
Suicidal ideation 1518 0.79 0.71–0.88 2.31 × 10−5 1.62 × 10−4* 1280 1.68 1.32–2.13 2.11 × 10−5 1.48 × 10−4*
Suicide attempt 1537 0.78 0.69–0.88 2.73 × 10−5 1.64 × 10−4* 1262 1.58 1.24–2.02 2.67 × 10−4 1.34 × 10−3*
Educational attainment 1636 1.17 1.06–1.29 2.77 × 10−3 8.31 × 10−3* 1319 1.06 0.85–1.33 5.93 × 10−1 1.00 × 100
Living together 1357 1.28 1.15–1.44 1.01 × 10−5 8.08 × 10−5* – – – – –
AAO, age at onset; PAO, polarity at onset; n, total number of participants from the Dutch and German cohorts.
* P < 0.05
a. After Bonferroni–Holm correction.





P Adjusted Pc n Estimate s.e.
Unadjusted
P Adjusted P
Number of manic episodes per illness
year
1436 0.11 0.03 7.08 × 10−5 3.54 × 10−4* 1156 −0.42 0.06 4.68 × 10−13 3.74 × 10−12*
Number of depressive episodes per
illness year
1231 0.07 0.03 1.93 × 10−2 3.86 × 10−2* 1051 0.12 0.06 4.63 × 10−2 1.85 × 10−1
AAO, age at onset; PAO, polarity at onset; n, total number of participants from the Dutch and German cohorts.
* P < 0.05
a. The number of manic/depressive episodes was divided by (years of illness) + 1. For secondary analyses of the number of episodes not corrected for the years of illness, see the
Supplementary Note 2.
b. Unstandardised beta coefficient.
c. After Bonferroni–Holm correction.
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Fig. 2 Results from the genome-wide association study (GWAS), polygenic score (PGS) analyses, and heritability analyses.
(a) and (b) Results from analyses of PGS. For detailed results, see Supplementary Table S8. Significance levels: n.s., not significant, P > 0.05; nominal: P < 0.05; Bonferroni, below the
Bonferroni-corrected significance threshold corrected for 96 tests (P < 5.2 × 10−4). (a) Associations of PGSswith the AAO. For interpretability, the plot shows the untransformed AAO.
Significance levels are based on the analyses of the AAO after rank-based inverse-normal transformation (which was performed because the distribution of AAOwas highly skewed
and differed greatly across the study cohorts). (b) Associations of the top versus bottomAAO quartiles with the top versus bottom PGS quartiles. A higher odds ratio (OR) indicates an
associationwith higher AAO. (c) Manhattan plot of the discovery-stage AAOGWAS. (d) Locus-specific Manhattan plot of the top-associated AAO variant. (e) Estimation of the variance
in different phenotype definitions explained by genotyped single-nucleotide variants (SNV) (h2SNV). For the cohort wtccc, we directly estimated h
2
SNV from genotype data in GCTA
GREML; we estimated all other heritabilities from GWAS summary statistics using LDSC. The plot shows h2SNV estimates and s.e.
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; BD, bipolar disorder; cM, centi Morgan. Mbp, mega base pairs; MD, major depression; EA,
educational attainment; SNV, single-nucleotide variant; cont, continent; disorder type I; PAO, polarity at onset; PAO-M, mania/hypomania before depression; PAO-D, depression
before mania/hypomania; PAO-X, mixed; SZ, schizophrenia.
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However, this association was not replicated in an independent
sample of six cohorts (Supplementary Table S7, Supplementary
Fig. S2). In the replication sample (n = 2237), we had 76% power to
replicate this SNV at a P-value threshold of 0.1. The GWAS of
PAO did not yield any genome-wide significant findings, in either
primary (PAO-M/-X versus PAO-D) or secondary (PAO-M versus
PAO-D) analyses (Supplementary Fig. S3).
We also calculated PGSs for AAO and PAO using leave-one-out
summary statistics from these GWASs. The AAO PGS was nomin-
ally significantly associated with AAO (β = 0.23 years, s.e. = 0.08,
P = 0.0087, φ = 0.1, Fig. 2(a) and 2(b)) for five of six tested φ para-
meters but did not withstand correction for multiple testing
(Supplementary Table S8). The PAO PGS was not associated with
the PAO (Supplementary Fig. S4).
SNV-based heritability of the investigated phenotypes
Weestimated the SNV-based heritability h2SNV directly from genotype
data using GCTA in the only cohort large enough for this analysis,
wtccc. For the AAO, the h2SNV in wtccc was estimated at 0.63 (P =
0.0026) (Fig. 2(e)). We evaluated the robustness of this estimate by
resampling (mean h2SNV = 0.62, resampling 95% CI 0.15–1.00).
We next estimated h2SNV by linkage disequilibrium score
regression (LDSC) from the GWAS summary statistics generated in
the present study (Fig. 2(e)). We observed that the heritability
decreased when cohorts, phenotype definitions and continents were
combined (for example ‘diagnostic interview’ in North America:
AAO h2SNV = 0.16, 95% CI 0–0.40, ‘impairment/help-seeking’ in
Europe: h2SNV = 0.03, 95% CI 0–0.25, all combined h
2
SNV = 0.05,
95% CI 0–0.12). As a result of the insufficient sample size, we could
not estimate the h2SNV of impairment/help-seeking in North America
and diagnostic interview in Europe. For depression versus (hypo)
manic and mixed PAO, h2SNV was 0.17 (95% CI 0.05–0.29) on the
observed scale.
Discussion
In our study of bipolar disorder disease onset, we first evaluated the
association between AAO or PAO with several clinical indicators of
severity in a sample of 1659 patients.We showed that an earlier onset
is associated with increased severity, demonstrating and replicating
the clinical relevance of these phenotypes. Next, we performed
genetic analyses including 12 977 patients from 34 cohorts. Here,
we demonstrated that higher genetic risk for ASD, major depression,
schizophrenia and educational attainment is associated with an
earlier AAO, providing evidence that the age at bipolar disorder
onset is influenced by a broad liability for psychiatric illness.
Third, we performed GWAS to identify genetic variants asso-
ciated with the AAO and PAO, which did not yield any replicated
associations. Fourth, we outlined the extent to which age (and,
partly, polarity) at onset varies across cohorts, depending both on
the continent of recruitment and on the diagnostic instrument
used to determine the AAO.
Finally, we showed that this substantial phenotypic heterogen-
eity affects the heritability of the phenotype, which decreased
when multiple cohorts with different diagnostic instruments were
combined. This analysis emphasises how genetic analyses are
hampered by phenotypic heterogeneity.
Illness onset is associated with disease course
In a first set of analyses, we confirmed the clinical relevance of
disease onset phenotypes in bipolar disorder. Age at bipolar dis-
order onset was associated with important illness severity indica-
tors, such as suicidality, psychotic symptoms and lower
educational attainment, thereby replicating findings of previous
studies.22,25 Furthermore, patients with a depressive bipolar dis-
order onset had an increased reported lifetime suicidality, whereas
those with a (hypo)manic onset were more likely to experience delu-
sions and more manic episodes per illness year. Contrary to previ-
ous evidence in a US (but not in a French) sample, we observed that
an earlier onset was associated with fewer episodes per illness year.26
Of note, when not normalising for the illness duration, the AAO
was, as expected, positively correlated with the number of episodes
(see Supplementary Note 2).
Increased genetic scores for neuropsychiatric
phenotypes predict an earlier illness onset
Higher PGSs for schizophrenia, major depression, ASD and educa-
tional attainment were significantly associated with a lower AAO,
and none of the tested PGSs were significantly associated with
PAO. Our findings support the hypothesis that a general liability
for psychiatric disorders influences an earlier age of onset in
bipolar disorder. Alternatively, an earlier onset may also reflect
the broader phenotypic spectrum sometimes captured in early-
onset bipolar disorder. Unexpectedly, and in contrast to several
other disorders (for example multiple sclerosis), where the strongest
genetic risk factors for disease liability are also the most important
genetic factors associated with an earlier disease onset,6,27 we did not
find a significant association between bipolar disorder PGS and the
age at bipolar disorder onset. Statistical power may have influenced
this result, as the sample sizes of both the schizophrenia and major
depression GWASs were larger than that of the bipolar disorder
GWAS, improving the predictive ability of these PGSs compared
with the bipolar disorder PGS.
The described significant relationship of higher educational attain-
ment PGS with an earlier AAO may seem counterintuitive. However,
several studies described a significant association, genetic correlation
and causal relationship between a higher educational attainment and
bipolar disorder risk.28,29 Our findings demonstrate that a high educa-
tional attainment PGS is not only a risk factor for bipolar disorder but
also associated with an earlier onset of the disorder.
Lack of replication of the GWAS finding
We have conducted two GWASs to identify individual loci influen-
cing the age and polarity at bipolar disorder onset, possibly inde-
pendently of affecting lifetime disorder risk. Our discovery GWAS
prioritised a genome-wide significant locus associated with the
AAO. However, the lack of replication suggests that this finding
may have been false-positive. This failure to replicate could have
been because of insufficient statistical power in the replication
sample, as our power analysis did not account for the likely pheno-
typic and genetic heterogeneity across cohorts and may thus have
underestimated the necessary sample size. Importantly, the replica-
tion sample was more ethnically diverse than the discovery sample,
which reduced the statistical power. The PAOGWAS, with its lower
sample size and dichotomous phenotype, did not identify any
genome-wide significant locus.
We also calculated an AAO PGS using our GWAS and tested it
on our sample. Although the effect size of this PGS on the AAO was
substantial (0.23 years per unit change in the PGS), the association
was only nominally significant.
The heterogeneity of phenotype definitions
A striking finding of our study was the systematic difference in the
AAO distribution across cohorts, continents and assessment strat-
egies. Although the assessment strategies varied considerably by
continent, with diagnostic interview being mainly used in North
Genetics of disease onset in bipolar disorder
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America and impairment/help-seeking in Europe, we showed that
the continent-level differences were partially independent from
the AAO assessment strategy and that both factors contributed sig-
nificantly to the heterogeneity (Supplementary Table S6). However,
variations in the demographic structure of analysed populations
may have biased the assessed AAO of bipolar disorder, contributing
to the observed differences. Although prior research has identified
AAO differences across continents (for example the incidence
of early-onset bipolar disorder is higher in the USA than in
Europe)30 this study is the first to systematically assess this hetero-
geneity across many cohorts with different ascertainment strategies.
For the polarity at disease onset, the relative proportion of
patients reporting a depressive index episode did not differ across
continents but across instruments. A (hypo)manic onset was
more common if the onset was based on an impairment/help-
seeking instead of diagnostic interview phenotype definition.
Phenotypic heterogeneity affects genetic analyses
Interestingly, the systematic differences in AAO phenotypes across
cohorts are reflected in heritability estimates: we observed the
highest SNV-based heritability h2SNV when onset was established
by diagnostic interview and the lowest when it was captured with
more health system-specific and subjective measurements, such as
item 4 of the Operational Criteria Checklist for Psychotic Illness
(impairment/help-seeking). Moreover, h2SNV estimates approached
zero when all samples were combined in our primary analysis
(h2SNV = 0.05; 95% CI 0–0.12), underscoring the strong impact of
phenotypic heterogeneity. For PAO-M/-X versus PAO-D, we
observed significant h2SNV estimates, demonstrating that genetic
factors contribute to the polarity at bipolar disorder onset.
Thus, we not only showed systematic heterogeneity in a clinic-
ally relevant psychiatric phenotype across cohorts but also provided
direct evidence for how this heterogeneity can hamper genetic
studies. Similarly, a recent investigation demonstrated that the
phenotyping method (for example diagnostic interview versus
self-report) significantly influenced heritability estimates, GWAS
results and PGS performance in analyses of major depression sus-
ceptibility, with broader phenotype definitions resulting in lower
heritability estimates.31 These results indicate that although increas-
ing samples sizes generally improves the power to detect significant
associations, larger samples are no silver bullet: careful phenotype
harmonisation and uniform recruitment strategies are likely at
least as important.
Limitations
In addition to diverse phenotype definitions originating from differ-
ent ascertainment methods, as described above, several factors may
have limited the cross-cohort comparability of the AAO and PAO.
These factors include differences in the definition and ascertainment
of the age at bipolar disorder onset and in how bipolar disorder
was diagnosed across cohorts and continents. Such differences can
lead to bias, affecting genetic analyses. For example, as patients
diagnosed with bipolar disorder type II show, on average, later
ages at onset than patients with bipolar disorder type I,32 differing
proportions of bipolar disorder subtypes across cohorts may have
an impact on AAO analyses. Therefore, we included the bipolar dis-
order subtype as a covariate in our genetic analyses to control for this
confounder. Still, this cross-cohort heterogeneity has likely reduced
our statistical power.
Given that, for all included cohorts, the disease onset pheno-
types were assessed retrospectively, measurement errors associated
with interrater reliabilities and recall bias may have occurred across
cohorts. For example, hypomania was likely underreported, poten-
tially biasing the PAO towards depression. Notably, such potential
issues are not specific to the present study but may affect all retro-
spective analyses of psychiatric phenotypes. Nevertheless, differ-
ences in the diagnosis of bipolar disorder and the ascertained
phenotypes between cohorts might have exacerbated these
problems. Therefore, future studies should focus on compiling
clinically more homogeneous, phenotypically better-harmonised
data-sets instead of only assembling the largest possible sample.
Furthermore, the rank-based inverse normal transformation of
the AAO phenotype may have affected the GWAS and heritability
analyses. We conducted this transformation because, first, the ori-
ginal AAO distribution was highly skewed and thus not suitable
for linear regression and, second, the AAO differed significantly
between cohorts, which could have biased the meta-analysis.
However, by transforming the data, only the rank and not the abso-
lute differences in onset between patients was maintained, reducing
the interpretability of the phenotype and the genetic effects.
We performed both SNV-level and polygenic score associations
using a structured meta-analysis, which mitigates some of the noise
introduced by phenotypic heterogeneity. However, we were unable
to account for differences in the underlying genetic aetiology of the
phenotypes across cohorts. As described above, phenotypic hetero-
geneity is an important limitation of our study and should be
considered in future phenotype and genetic analyses. Our results
need to be interpreted in light of these limitations.
Implications
Phenotypes of bipolar disorder onset are clinically important trait
measures contributing to the well-known clinical and biological het-
erogeneity of this severe psychiatric disorder. Genetic analysis of
AAO and PAO may lead to a better understanding of the biological
risk factors underlying mental illness and support clinical assess-
ment and prediction. Our study provides evidence of a genetic con-
tribution to age and polarity at bipolar disorder onset but also
demonstrates the need for systematic harmonisation of clinical
data on bipolar disorder onset in future studies.
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